TCWP’s Bio-Rad Laboratories Class A BIO Stock Holding History

TCWP’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-86	Closed	-$48K	–	441
2022 Q1	$48K	Buy	+86	New	+$51.8K	0.01%	485

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

TCWP's BIO Position: Q2 2022 in Review

TCWP sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 86 shares — an estimated $48K sold.

TCWP first reported a position in BIO in Q1 2022 and held it in 1 quarter. The position peaked at $48K in Q1 2022. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

TCWP reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
TCWP sold 86 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $48K.
TCWP first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and held it in 1 quarter.
TCWP's Bio-Rad Laboratories Class A position peaked at $48K in Q1 2022.
500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.